Patents Assigned to SHANGHAI CELLULAR BIOPHAMACEUTICAL GROUP LTD.
  • Publication number: 20210214789
    Abstract: The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.
    Type: Application
    Filed: January 21, 2019
    Publication date: July 15, 2021
    Applicants: SHANGHAI CELLULAR BIOPHAMACEUTICAL GROUP LTD., WUXI CELLULAR BIOPHAMACEUTICAL GROUP LTD.
    Inventors: Fang Liu, Liping Lan, Yutian Wei, Xun Ye, Li Zhang, Jiaqi Huang, Yihong Yao